Amanda Gammon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amanda Gammon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Deborah W. Neklason
Utah Center of Genetic Discovery, University of Utah, Salt Lake City, UT, USA
2 shared publications - Wendy Kohlmann
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2 shared publications - Alison Fraser
University of Utah Huntsman Cancer Institute, Salt Lake City, UT
1 shared publication - Anita Yeomans Kinney
Department of Biostatistics and Epidemiology, Rutgers University School of Public Health, Piscataway, USA
1 shared publication - Bryony A. Thompson
Department of Pathology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
1 shared publication - Cathryn Koptiuch
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112
1 shared publication
Latest Publications
- Open Access
- 27 June 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Pancreatic cancer as a sentinel for hereditary cancer predisposition
Genes associated with hereditary breast and ovarian cancer (HBOC) and colorectal cancer (CRC) predisposition have been shown to play a role in pancreatic cancer susceptibility. Growing evidence suggests that pancreatic cancer may be useful as a sentinel cancer to identify families that could benefit from HBOC or CRC surveillance, but to date pancreatic cancer is only considered an indication for genetic testing in the context of additional family history. Preliminary data generated at the Huntsman Cancer Hospital (HCH) included variants identified on a custom 34-gene panel or 59-gene panel including both known HBOC and CRC genes for respective sets of 66 and 147 pancreatic cancer cases, unselected for family history. Given the strength of preliminary data and corresponding literature, 61 sequential pancreatic cancer cases underwent a custom 14-gene clinical panel. Sequencing data from HCH pancreatic cancer cases, pancreatic cancer cases of the Cancer Genome Atlas (TCGA), and an unselected pancreatic cancer screen from the Mayo Clinic were combined in a meta-analysis to estimate the proportion of carriers with pathogenic and high probability of pathogenic variants of uncertain significance (HiP-VUS). Approximately 8.6% of unselected pancreatic cancer cases at the HCH carried a variant with potential HBOC or CRC screening recommendations. A meta-analysis of unselected pancreatic cancer cases revealed that approximately 11.5% carry a pathogenic variant or HiP-VUS. With the inclusion of both HBOC and CRC susceptibility genes in a panel test, unselected pancreatic cancer cases act as a useful sentinel cancer to identify asymptomatic at-risk relatives who could benefit from relevant HBOC and CRC surveillance measures.
- 27 June 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Open AccessPancreatic cancer as a sentinel for hereditary cancer predisposition
Genes associated with hereditary breast and ovarian cancer (HBOC) and colorectal cancer (CRC) predisposition have been shown to play a role in pancreatic cancer susceptibility. Growing evidence suggests that pancreatic cancer may be useful as a sentinel cancer to identify families that could benefit from HBOC or CRC surveillance, but to date pancreatic cancer is only considered an indication for genetic testing in the context of additional family history. Preliminary data generated at the Huntsman Cancer Hospital (HCH) included variants identified on a custom 34-gene panel or 59-gene panel including both known HBOC and CRC genes for respective sets of 66 and 147 pancreatic cancer cases, unselected for family history. Given the strength of preliminary data and corresponding literature, 61 sequential pancreatic cancer cases underwent a custom 14-gene clinical panel. Sequencing data from HCH pancreatic cancer cases, pancreatic cancer cases of the Cancer Genome Atlas (TCGA), and an unselected pancreatic cancer screen from the Mayo Clinic were combined in a meta-analysis to estimate the proportion of carriers with pathogenic and high probability of pathogenic variants of uncertain significance (HiP-VUS). Approximately 8.6% of unselected pancreatic cancer cases at the HCH carried a variant with potential HBOC or CRC screening recommendations. A meta-analysis of unselected pancreatic cancer cases revealed that approximately 11.5% carry a pathogenic variant or HiP-VUS. With the inclusion of both HBOC and CRC susceptibility genes in a panel test, unselected pancreatic cancer cases act as a useful sentinel cancer to identify asymptomatic at-risk relatives who could benefit from relevant HBOC and CRC surveillance measures.
- Open Access
- 1 July 2016
- Published by Taylor & Francis in The Application of Clinical Genetics
- Vol. ume 9, 83-92
Genetic basis of Cowden syndrome and its implications for clinical practice and risk management
Cowden syndrome (CS) is an often difficult to recognize hereditary cancer predisposition syndrome caused by mutations in phosphatase and tensin homolog deleted on chromosome 10 (PTEN). In addition to conferring increased cancer risks, CS also predisposes individuals to developing hamartomatous growths in many areas of the body. Due to the rarity of CS, estimates vary on the penetrance of certain phenotypic features, such as macrocephaly and skin findings (trichilemmomas, mucocutaneous papules), as well as the conferred lifetime cancer risks. To address this variability, separate clinical diagnostic criteria and PTEN testing guidelines have been created to assist clinicians in the diagnosis of CS. As knowledge of CS increases, making larger studies of affected patients possible, these criteria continue to be refined. Similarly, the management guidelines for cancer screening and risk reduction in patients with CS continue to be updated. This review will summarize the current literature on CS to assist clinicians in staying abreast of recent advances in CS knowledge, diagnostic approaches, and management.
- 1 July 2016
- Published by Taylor & Francis in The Application of Clinical Genetics
- Vol. ume 9, 83-92
Open AccessGenetic basis of Cowden syndrome and its implications for clinical practice and risk management
Cowden syndrome (CS) is an often difficult to recognize hereditary cancer predisposition syndrome caused by mutations in phosphatase and tensin homolog deleted on chromosome 10 (PTEN). In addition to conferring increased cancer risks, CS also predisposes individuals to developing hamartomatous growths in many areas of the body. Due to the rarity of CS, estimates vary on the penetrance of certain phenotypic features, such as macrocephaly and skin findings (trichilemmomas, mucocutaneous papules), as well as the conferred lifetime cancer risks. To address this variability, separate clinical diagnostic criteria and PTEN testing guidelines have been created to assist clinicians in the diagnosis of CS. As knowledge of CS increases, making larger studies of affected patients possible, these criteria continue to be refined. Similarly, the management guidelines for cancer screening and risk reduction in patients with CS continue to be updated. This review will summarize the current literature on CS to assist clinicians in staying abreast of recent advances in CS knowledge, diagnostic approaches, and management.
- 1 October 2015
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 24 (4) , 667-681
Confidentiality & the Risk of Genetic Discrimination
- 1 October 2015
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 24 (4) , 667-681
Confidentiality & the Risk of Genetic Discrimination
- 20 January 2013
- Published by Wiley in Clinical Genetics
- Vol. 84 (6) , 593-595
PTEN mosaicism with features of Cowden syndrome
We present the first known case of somatic PTEN mosaicism causing features of Cowden syndrome (CS) and inheritance in the subsequent generation. A 20‐year‐old woman presented for genetics evaluation with multiple ganglioneuromas of the colon. On examination, she was found to have a thyroid goiter, macrocephaly, and tongue papules, all suggestive of CS. However, her reported family history was not suspicious for CS. A deleterious PTEN mutation was identified in blood lymphocytes, 966A>G, 967delA. Genetic testing was recommended for her parents. Her 48‐year‐old father was referred for evaluation and was found to have macrocephaly and a history of Hashimoto's thyroiditis, but no other features of CS. Site‐specific genetic testing carried out on blood lymphocytes showed mosaicism for the same PTEN mutation identified in his daughter. Identifying PTEN mosaicism in the proband's father had significant implications for the risk assessment/genetic testing plan for the rest of his family. His result also provides impetus for somatic mosaicism in a parent to be considered when a de novo PTEN mutation is suspected.
- 20 January 2013
- Published by Wiley in Clinical Genetics
- Vol. 84 (6) , 593-595
PTEN mosaicism with features of Cowden syndrome
We present the first known case of somatic PTEN mosaicism causing features of Cowden syndrome (CS) and inheritance in the subsequent generation. A 20‐year‐old woman presented for genetics evaluation with multiple ganglioneuromas of the colon. On examination, she was found to have a thyroid goiter, macrocephaly, and tongue papules, all suggestive of CS. However, her reported family history was not suspicious for CS. A deleterious PTEN mutation was identified in blood lymphocytes, 966A>G, 967delA. Genetic testing was recommended for her parents. Her 48‐year‐old father was referred for evaluation and was found to have macrocephaly and a history of Hashimoto's thyroiditis, but no other features of CS. Site‐specific genetic testing carried out on blood lymphocytes showed mosaicism for the same PTEN mutation identified in his daughter. Identifying PTEN mosaicism in the proband's father had significant implications for the risk assessment/genetic testing plan for the rest of his family. His result also provides impetus for somatic mosaicism in a parent to be considered when a de novo PTEN mutation is suspected.
- Open Access
- 21 June 2011
- Published by Wiley in Journal of Genetic Counseling
- Vol. 20 (6) , 625-638
Awareness and Preferences Regarding BRCA1/2 Genetic Counseling and Testing Among Latinas and Non‐Latina White Women at Increased Risk for Hereditary Breast and Ovarian Cancer
This study was an investigation of awareness, cognitions, and psychosocial and educational needs related to genetic counseling and testing among Latinas and non‐Latina whites at increased risk for having a BRCA1/2 mutation. Sixty‐three Latina and eighty‐four non‐Latina white women completed telephone surveys employing a mixture of quantitative and qualitative questions assessing awareness, benefits, risks, barriers, and genetic counseling communication preferences regarding BRCA1/2 testing. Among participants who had not previously had genetic counseling/testing, 56.9% of Latinas (29/51) and 34.8% of non‐Latina white participants (24/69) were unaware of the availability of BRCA1/2 testing. In multivariate logistic regression analysis, Latina ethnicity was the only statistically significant independent factor associated with lack of awareness (OR = 0.42; 95% CI = 0.19–0.35). No appreciable differences were noted between ethnic groups regarding perceived benefits of BRCA1/2 testing or desired genetic counseling topics. These findings underscore the importance of increasing awareness of cancer genetic counseling and genetic testing among both Latina and non‐Latina white populations.
- 21 June 2011
- Published by Wiley in Journal of Genetic Counseling
- Vol. 20 (6) , 625-638
Open AccessAwareness and Preferences Regarding BRCA1/2 Genetic Counseling and Testing Among Latinas and Non‐Latina White Women at Increased Risk for Hereditary Breast and Ovarian Cancer
This study was an investigation of awareness, cognitions, and psychosocial and educational needs related to genetic counseling and testing among Latinas and non‐Latina whites at increased risk for having a BRCA1/2 mutation. Sixty‐three Latina and eighty‐four non‐Latina white women completed telephone surveys employing a mixture of quantitative and qualitative questions assessing awareness, benefits, risks, barriers, and genetic counseling communication preferences regarding BRCA1/2 testing. Among participants who had not previously had genetic counseling/testing, 56.9% of Latinas (29/51) and 34.8% of non‐Latina white participants (24/69) were unaware of the availability of BRCA1/2 testing. In multivariate logistic regression analysis, Latina ethnicity was the only statistically significant independent factor associated with lack of awareness (OR = 0.42; 95% CI = 0.19–0.35). No appreciable differences were noted between ethnic groups regarding perceived benefits of BRCA1/2 testing or desired genetic counseling topics. These findings underscore the importance of increasing awareness of cancer genetic counseling and genetic testing among both Latina and non‐Latina white populations.
- 1 April 2009
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 23 (2) , 219-231
Hamartomatous polyposis syndromes
- 1 April 2009
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 23 (2) , 219-231
Hamartomatous polyposis syndromes
- 1 January 2007
- Published by S. Karger AG in Digestion
- Vol. 76 (1) , 7-19
Can We Identify the High-Risk Patients to Be Screened? A Genetic Approach
Our understanding of the mechanisms that lead to colorectal cancer expands each year. Patients with a genetic predisposition to colorectal cancer have significantly increased risks for developing this malignancy over their lifetime. These risks can approach an 80 to nearly 100% likelihood of colorectal malignancy with some of the known cancer predisposition syndromes [Burt and Neklason: Gastroenterology 2005;128:1696–1716 and Rowley: Annu Rev Med 2005;56:539–554]. Although these inherited syndromes have a genetic basis, affected individuals are often initially seen by medical professionals outside the genetics realm. Gastroenterologists in particular have a key role in identifying patients at high risk for an inherited colorectal cancer predisposition syndrome and referring them on for directed genetics evaluation. In this review, we will focus on the presenting features and recommended screening and treatment protocols for six syndromes that predispose to colorectal carcinoma. The underlying genetic basis of each syndrome will be discussed, as well as specific guidelines for patient identification. Familial adenomatous polyposis will be covered first, followed by Lynch syndrome, attenuated familial adenomatous polyposis, MYH-associated polyposis, hereditary mixed polyposis, and hyperplastic polyposis. Other rare syndromes (the hamartomatous polyposis syndromes) will be summarized in table form. Finally, we will give some general guidelines for when to first suspect colorectal cancer syndromes, a summary of family history taking techniques that can be used in the primary care setting and a review of the referral, genetics appointment and postgenetics consultation process. Through this review, we hope to show that the identification of high-risk patients is possible, though sometimes difficult.
- 1 January 2007
- Published by S. Karger AG in Digestion
- Vol. 76 (1) , 7-19
Can We Identify the High-Risk Patients to Be Screened? A Genetic Approach
Our understanding of the mechanisms that lead to colorectal cancer expands each year. Patients with a genetic predisposition to colorectal cancer have significantly increased risks for developing this malignancy over their lifetime. These risks can approach an 80 to nearly 100% likelihood of colorectal malignancy with some of the known cancer predisposition syndromes [Burt and Neklason: Gastroenterology 2005;128:1696–1716 and Rowley: Annu Rev Med 2005;56:539–554]. Although these inherited syndromes have a genetic basis, affected individuals are often initially seen by medical professionals outside the genetics realm. Gastroenterologists in particular have a key role in identifying patients at high risk for an inherited colorectal cancer predisposition syndrome and referring them on for directed genetics evaluation. In this review, we will focus on the presenting features and recommended screening and treatment protocols for six syndromes that predispose to colorectal carcinoma. The underlying genetic basis of each syndrome will be discussed, as well as specific guidelines for patient identification. Familial adenomatous polyposis will be covered first, followed by Lynch syndrome, attenuated familial adenomatous polyposis, MYH-associated polyposis, hereditary mixed polyposis, and hyperplastic polyposis. Other rare syndromes (the hamartomatous polyposis syndromes) will be summarized in table form. Finally, we will give some general guidelines for when to first suspect colorectal cancer syndromes, a summary of family history taking techniques that can be used in the primary care setting and a review of the referral, genetics appointment and postgenetics consultation process. Through this review, we hope to show that the identification of high-risk patients is possible, though sometimes difficult.